— Know what they know.
Not Investment Advice

NERV NASDAQ

Minerva Neurosciences, Inc.
1W: -3.5% 1M: -26.8% 3M: -33.3% YTD: -16.3% 1Y: +56.2% 3Y: -55.1% 5Y: -79.9%
$3.28
+0.05 (+1.55%)
 
Weekly Expected Move ±8.2%
$3 $3 $3 $4 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $152.8M mcap · 38M float · 0.586% daily turnover · Short 59% of daily vol

Balance Sheet Trends

Total Assets
$98M +163.8% ▲
5Y CAGR: +11.2%
Total Liabilities
$239M +279.9% ▲
5Y CAGR: +117.0%
Shareholders Equity
-$141M -447.8% ▼
Cash & Investments
$82M +285.3% ▲
5Y CAGR: +26.6%
Total Debt
$65M +0.0% ▲
5Y CAGR: +257.5%
Net Debt
-$17M +18.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$61M$36M$41M$21M$82M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$61M$36M$41M$21M$82M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$100K$4M$1M$907K$798K
Total Current Assets$62M$40M$42M$22M$83M
Property, Plant & Equip.$0$16K$11K$5K$0
Goodwill & Intangibles$15M$15M$15M$15M$15M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$0$0$0$0$0
Total Non-Current Assets$15M$15M$15M$15M$15M
Total Assets$77M$55M$57M$37M$98M
— Liabilities —
Accounts Payable$2M$970K$2M$2M$639K
Short-Term Debt$0$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$15K$591K$363K-$473
Total Current Liabilities$3M$1M$3M$3M$2M
Long-Term Debt$0$0$0$0$65M
Other Non-Current Liab.$66M$74M$82M$60M$171M
Total Non-Current Liabilities$66M$74M$82M$60M$236M
Total Liabilities$69M$75M$85M$63M$239M
— Equity —
Common Stock$534$534$699$699$4K
Retained Earnings-$335M-$367M-$397M-$395M-$689M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$8M-$20M-$28M-$26M-$141M
Total Liabilities & Equity$77M$55M$57M$37M$98M
— Key Metrics —
Total Debt$0$0$0$0$65M
Net Debt-$61M-$36M-$41M-$21M-$17M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms